Bonviva Effective as a Once-Monthly Oral Formulation for Osteoporosis - RxChemist.co.uk continues its lead in the provision of the newest prescription medication to its customers. Ibandronate (ibandronic acid) once monthly (Bonviva 150mg) received a positive opinion on granting a marketing authorisation from the European Medicines Evaluation agency in June 2005. The licensed indication for ibandronate once monthly will be the treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures.
International Press Release Publishing for free in 15 languages across 22 countries
Press Releases
Google-Suche:
 

Send this page to somebody

Fill in the email address of your friend to send an email with the address.
Address info
(Required)
The e-mail address to send this link to.
(Required)
Your email address.
A comment about this link.
SUBCATEGORIES
Women's Health
 
 
Pressreleases by authors
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z